Century Therapeutics, Inc. (NASDAQ:IPSC – Get Free Report) has earned a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Century Therapeutics in a research report on Thursday, July 2nd. Get Century Therapeutics alerts:Get Our Latest Report on Century TherapeuticsInstitutional Investors Weigh In On Century TherapeuticsCentury Therapeutics Stock Up 5.2%Several institutional investors have recently made changes to their positions in the stock. On average, equities analysts expect that Century Therapeutics will post -0.43 EPS for the current fiscal year. Further ReadingReceive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.